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This article provides a brief description of some of the most remarkable sessions of the @EuroRespSoc 
Lung Science Conference and the Sleep and Breathing Conference 2021 and presents the new incoming 
members of the ECMC (@EarlyCareerERS) https://bit.ly/2RSDP40
The Lung Science Conference (LSC) and the 
Sleep and Breathing Conference (SBC) are two 
conferences organised by the European Respiratory 
Society (ERS), the latter held in association with 
the European Sleep Research Society. This year, 
the LSC and SBC were both held in a virtual format 
with the participation of researchers and clinicians 
from around the world. The participation of Early 
Career Members (ECMs) was notable in both events: 
216 of 363 (60%) delegates attending the LSC 
were under 40 years old, and 315 of 920 (34%) 
delegates were ≤40 years of age at the SBC. Both 
conferences included outstanding talks on the 
most recent advances in respiratory medicine and 
science, oral/poster communication sessions on 
novel research, exciting opportunities to network 
with peers, and much more!
This paper provides a brief overview of some of 
the most remarkable sessions of the LSC and SBC, 
written by ECMs attending the sessions.
We also present the new members of the Early 
Career Member Committee (ECMC) of the ERS from 
Assemblies 1, 4, 10, 12 and 13, who were elected in 
the latest round of ERS elections. Welcome aboard!
LSC Highlights 2021: Repair 
and regeneration in chronic 
lung disease and lung cancer
The LSC 2021 on “Repair and regeneration in 
chronic lung disease and lung cancer” was held 
in a virtual format on 11–12 March 2021. In 
addition to an outstanding scientific programme, 
the LSC provides excellent opportunities for career 
development and inclusion of ECMs. Poster sessions 
were chaired by an ECM who was paired with a 
senior faculty member to allow ECMs to become 
acquainted with session chairing. In addition, the 
ECM authors of highly scored abstracts were able 
to take part in an online mentorship session. The 
ECMC organised a session specifically for ECMs on 
“Research output for career advancement”. Below, 
we describe the scientific highlights of LSC 2021 for 
those who could not attend and for those who wish 
to recall the sessions. The most important take-
home messages of the LSC sessions are provided 
in table 1.
The ERS presents several awards at the LSC. 
The five highest ranked abstracts from ECMs 
were presented during the Young investigator 
session. Martina De Santis received the William 
MacNee Award for the best presentation in this 
session. In addition, the organisers presented 
eight Distinguished Poster Awards to Naoaki 
Wantanabe, Ian Hawthorne, Róisín Mongey, 
Georgia Giotopoulou, Manuela Platé, Carolin Koss, 
Cinta Iriondo and Emil Rehnberg for their excellent 
contributions during the poster sessions.
Opening lecture
The opening lecture of the LSC was delivered by 
Naftali Kaminski (New Haven, USA). In this talk, 
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Prof. Kaminski challenged the audience to consider 
whether pulmonary fibrosis, a disease usually 
associated with ageing, is driven by aberrant lung 
developmental processes.
Idiopathic pulmonary fibrosis (IPF) has been 
the subject of escalating research efforts in 
recent years. The current paradigm is that IPF 
occurs secondary to repetitive alveolar epithelial 
microinjuries in predisposed individuals, with the 
activation, migration, and proliferation of fibroblasts 
and macrophages with matrix remodelling [1]. 
However, this model does not explain many 
characteristic features of IPF, such as myofibroblast 
foci, honeycomb cysts and traction bronchiectasis, 
in addition to the relentlessly progressive nature of 
this disease.
The possibility that IPF may involve the abnormal 
reactivation of developmental signalling was first 
suggested over a decade ago [2]. Since then, 
transcriptomic analysis of human lung has revealed 
Table 1 Take-home messages from the ERS Lung Science Conference 2021
Session Type Take-home messages
Opening lecture Developmental programmes are reactivated in idiopathic pulmonary fibrosis 
and may represent an attempt at alveologenesis in the damaged lung.
Cell plasticity in lung 
development and 
disease
Invited lectures Innovative methods such as single cell RNA sequencing (scRNASeq) and lineage 
tracing can be used to characterise distinct cellular populations in the lungs.
Induced pluripotent stem cells (iPSCs) could be useful tools for the study of 
lung disease and regeneration.
Stem cell niche 
interactions
Symposium External factors can impact the interaction between lipofibroblasts and 
alveolar type 2 (AT2) cells.
The alveolar type 1 (AT1) cell is a signalling hub during alveologenesis.
Epithelial stem cell in 
disease
Symposium Regarding squamous cell lung cancer (SqCC), step wise progression from 
metaplasia to carcinoma in situ and finally to invasive carcinoma is not 
irreversible and progressive samples had greater somatically acquired genetic 
damage than regressive samples.
Lung cancers in smokers are clearly separated from lung cancers in 
nonsmokers based on the molecular and genetic analysis.
Club cells are important in alveolar maintenance and carcinogenesis and may 
be a therapeutic target against premalignancy and chronic lung disease.
Lessons from limb 
regeneration of the 
axolotl
Keynote lecture The understanding of molecular mechanisms of highly regenerative species 
may allow for uncovering processes for (re)activation of regenerative 
pathways in regeneration-incompetent species.
Cell–matrix interactions 
in the lung and beyond
Invited lectures The extracellular matrix affects cell behaviour in several ways including 
mechanical cues, structure, composition, alignment and topology. 
Such effects have several implications on immune response, stem cell 
differentiation, cellular proliferation, and disease state.
Therapies: organoids, 
drugs, cell therapy
Invited lectures Lung organoid culture techniques can be used to understand mechanisms of 
lung disease.
Novel techniques can be used to better understand the clinical effect of 
mesenchymal stromal cell (MSC) therapy.
Cellular reprogramming of cancer cells to antigen-presenting cells 
downregulates their tumourigenic capacity.
Early-career delegates 
session
Symposium Pre-prints are important to accelerate science communication, facilitate 
networking.
“Peer review” is a tool for scientific gatekeeping. Poor experimental design, 
unjustified conclusion, poor readability, poor introduction and poor review of 
literature, poorly described methods, confusing presentation are considered 
as reasons of getting rejections.
Aim, Audience, Awareness, Articulation are the 4A principles of successful 
scientific writing.
An ideal editorial should be an opinion maker, reconciliatory as well as 
providing its own intellectual contribution rather than just repeating or 
summarising findings of the publication it refers to.
Young investigator 
session
Oral presentations Outstanding talks were given by early career scientists on their most recent 
advances in respiratory medicine and science.
Breathe | 2021 | Volume 17 | No 3 3
Highlights of the ERS LSC and SBC 2021 and the new ECMC members
that numerous developmental pathways, including 
wingless-integration (WNT), sonic hedgehog (SHH), 
transforming growth factor (TGF)-β and bone 
morphogenetic protein (BMP) associated signalling 
are activated in the IPF lung [3]. Furthermore, the 
microRNA profile of the IPF lung is very similar to 
that seen in fetal lung, yet distinct from the healthy 
adult lung [4]. These data imply that a reversal of 
lung differentiation may occur in IPF, resulting in 
the expression of developmental markers.
Further data to support this hypothesis came 
from a large single cell RNA sequencing (scRNASeq) 
study of lungs from patients with and without IPF. 
The IPF Cell Atlas is an open access resource of 
scRNASeq data from over 300 000 cells covering 
all human lung cell types (www.ipfcellatlas.com). 
This work demonstrated dramatic alterations to 
epithelial cells within IPF lungs, with reduced 
numbers of type 1 and type 2 alveolar epithelial 
cells and increased numbers of airway epithelial 
cells. A novel population of epithelial cells, termed 
aberrant basaloid cells, was also identified in IPF 
lungs. These cells co-express basal epithelial, 
mesenchymal, senescence and developmental 
markers, and are located adjacent to myofibroblast 
foci [5]. Importantly, these aberrant basaloid cells 
express the development-associated transcription 
factors SOX-9 and SOX-11 [5], supporting the 
evidence for the involvement of developmental 
pathways in IPF.
In addition to the epithelial alterations, changes 
were seen in other cell populations. The RNA 
expression profiles of IPF lung endothelial cells 
shifted from that of specialised alveolar endothelial 
cells to a bronchial vascular endothelial cell pattern 
[5]. Furthermore, a subpopulation of myofibroblast-
like alveolar fibroblasts accumulated in IPF lungs, 
which may be related to cells that drive alveolar 
septation during alveolarisation. Overall, these 
data suggest a reactivation of developmental 
programmes in IPF.
Prof. Kaminski concluded with the thought-
provoking hypothesis that the altered cellular 
populations found in the IPF lung may result from 
a failed attempt at alveologenesis, with the aim 
of re-establishing normal alveolar respiratory 
units. Future work is required to confirm or refute 
this hypothesis, and the answer will be highly 
anticipated by those working in this field.
Cell plasticity in lung development 
and disease
Killian Hurley (Dublin, Ireland) started this session by 
discussing how induced pluripotent stem cell (iPSC)-
derived cells could be used as tools to understand 
lung regeneration and disease. Alveolar type 2 (AT2) 
epithelial cells are central to the pathogenesis of 
many diseases, but primary AT2s are difficult to 
obtain for in vitro studies. Induced type 2 epithelial 
cells (iAEC2s) can be derived from iPSCs generated 
from blood samples. In this 28-day protocol, iPSCs 
are cultured with small molecules and growth 
factors which promote the differentiation of 
iPSCs through endoderm progenitors, eventually 
reaching NK2 homeobox 1-expressing (NKX2-1+) 
primordial lung progenitors which differentiate into 
iAEC2s in three-dimensional (3D) culture [6, 7]. 
However, the cells resulting from this protocol are 
heterogeneous and a significant proportion lose 
their lung (NKX2-1+) phenotype [8]. A scRNAseq 
study of NKX2-1+ progenitor cells at various 
timepoints of this protocol revealed a bifurcation 
of cellular differentiation into lung and non-lung 
endodermal cell fates [9]. Importantly, this work 
found that a reduction in WNT signalling at day 
17.5 of the protocol gave the optimal yield of the 
target NKX2-1+ iAEC2s [9], which have numerous 
practical applications for disease models [10].
Next, Joo-Hyeon Lee (Cambridge, UK) described 
the journey of alveolar stem cell differentiation 
during alveolar regeneration. AT2 cells are essential 
for alveolar regeneration following injury, and 
differentiation of AT2 into alveolar type 1 (AT1) cells 
facilitates alveolar repair. Using data from scRNAseq, 
in vivo lineage tracing, and organoid models, 
a distinct AT2 cell population called damage-
associated transient progenitors (DATPs) has been 
identified. During alveolar regeneration, interstitial 
macrophage-derived interleukin (IL)-1β primes IL-1 
receptor-1-expressing AT2 cells to differentiate 
into DATPs via a hypoxia inducible factor (HIF)-1α-
mediated glycolysis pathway [11]. These DATPs can 
subsequently differentiate into mature AT1 cells. 
Notably, chronic inflammatory states mediated by 
IL-1β, such as IPF and lung adenocarcinoma, prevent 
AT1 differentiation, resulting in DATP accumulation 
and impaired alveolar regeneration [11]. Overall, 
these data suggest that DATPs are important for lung 
repair, and dysregulation of DATPs may contribute 
to lung disease.
Finally, Joachim Schultze (Bonn, Germany) 
discussed macrophage plasticity in COPD. 
scRNAseq data of immune cells obtained from 
the bronchoalveolar lavage fluid (BALF) of patients 
with COPD and healthy controls revealed that most 
BALF immune cells are derived from monocytes 
or macrophages. Furthermore, over 10 different 
macrophage subsets have been identified 
according to their gene expression profiles. 
While these macrophage subtypes share many 
aspects of their gene expression profiles, some 
expression patterns were specific to individual cell 
types. In COPD, alveolar macrophages expressed 
less HLA-related genes, increased proliferation 
markers, and increased markers of monocyte-
like macrophages than cells from controls. The 
predicted pathways that lead to this reprogramming 
of alveolar macrophages in COPD include NOTCH, 
WNT, TGF-β, tumour necrosis factor (TNF), and 
circadian-rhythm-rated genes. This work has 
given great insight into the pathways that drive 
macrophage differentiation which are relevant to 
the pathogenesis of COPD [12].
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Stem cell niche interactions
The lung has an endogenous capacity for repair and 
regeneration after lung injury. To better understand 
how this repair occurs and why it is aberrant in some 
chronic lung diseases, there have been substantial 
efforts to identify the signals regulating lung stem 
cell self-renewal and differentiation. In this session, 
lung stem cell niche interactions were discussed.
Saverio Bellusci (Giessen, Germany) opened this 
session by describing the epithelial–mesenchymal 
interactions involving fibroblast growth factors 
(FGFs). He described the interaction of lipofibroblasts 
with AT2 cells that allow for AT2 self-renewal. 
External factors including diabetes, obesity, sex 
and ageing can impact on the interaction between 
lipofibroblasts and AT2 cells, with a progressive loss 
of function of lipofibroblasts and decline in AT2 cell 
renewal. When a viral infection occurs, AT2 cells 
are damaged and lose their renewal abilities as 
lipofibroblasts differentiate into myofibroblasts. 
Prof. Bellusci concluded his presentation by 
proposing that TGF-β inhibitors could be potential 
candidates to reverse deranged repair in the alveolar 
epithelium.
The next talk focused on the role of the 
microvascular niche and AT1 cells in lung 
regeneration. Edward Morrisey (Pennsylvania, 
USA) discussed the endothelial heterogeneity in 
the alveolus, including CD34hi/Car4hi endothelial 
cells which express high levels of angiogenic 
factors and are probably important in guiding AT1 
development and behaviour [13]. Prof. Morrisey 
further explained how the endothelial cell landscape 
changes after influenza infection, with an increase 
of proliferating endothelial cells. These proliferating 
endothelial cells form a signalling niche in the 
alveolus after injury, regulating AT1 and AT2 cell 
and mesenchymal cell population proliferation. 
Next, the role of AT1 cells was discussed in more 
detail. AT1 cells are usually described as simple 
structural cells required for gas diffusion. By 
showing scRNASeq data, Prof. Morrisey proposed 
a new role for the AT1 cell: a signalling niche during 
alveologenesis [14]. AT1 cells play an important 
role not only for lung development but also for 
lung regeneration and repair and this can have big 
implications for diseases such as IPF and COPD.
Epithelial stem cell in disease
Sam Janes (London, UK) started the session with 
the topic “Tobacco smoking and somatic mutations 
in human bronchial epithelium”. Detecting and 
treating lung cancer earlier was the rationale of the 
presentation. Regarding squamous cell lung cancer 
(SqCC), stepwise progression (from metaplasia to 
carcinoma in situ and finally to invasive carcinoma) 
was mentioned not to be irreversible. Prof. Janes 
gave examples of the analysis of pre-invasive lung 
adenocarcinoma in situ (CIS) lesions in two patients. 
One patient was diagnosed with CIS and, after stable 
disease for 2 years, an index biopsy in the fourth year 
showed progression to invasive lung cancer. The 
second patient, with CIS detected at the beginning, 
showed regression to low grade dysplasia or normal 
epithelium by index biopsy after 4–6 years [15]. 
Comparison of progressive and regressive lesions 
regarding genetic analysis showed differences. 
Progressive samples had greater somatically 
acquired genetic damage than regressive samples. 
Progressive and regressive lesions have distinct 
transcriptomic and epigenetic profiles. Genomic, 
epigenetic and transcriptomic aberrations in genes 
involved in MHC class I antigen presentation are 
more prevalent in progressive than regressive 
lesions [16]. Prof. Janes also pointed out that, to 
understand cancer development, comparisons are 
required with normal tissues. Prof. Janes showed 
the differences between children, never-smokers, 
ex-smokers and current smokers. In the smokers’ 
samples, the number of substitutions occurring with 
age and the effects of smoking status indicated that 
smokers had more damage and that also quitting 
smoking allowed the expansion of cells that do not 
carry smoking’s mutational background [17].
Georgios Stathopoulos (Munich, Germany) talked 
about club cells in adenocarcinoma and alveolar 
repair. He started with the role of stem cells in 
COPD and lung cancer pathogenesis [18, 19]. Stem 
cells include not only basal cells, AT2 cells and 
undifferentiated progenitor cells, but also the club 
cells. Prof. Stathopoulos further discussed the role of 
replicative stress or environmental oncogenesis on 
stem cell mutations and abnormal cell proliferation. 
Regarding the underlying mechanisms, the type 
of cancer is important; whether it is smoking-
induced lung cancer or not, because lung cancers 
in smokers are clearly separated from lung cancers 
in nonsmokers based on the molecular and genetic 
analysis [20]. Based on the molecular hallmarks of 
smoking, KRAS and TP53 mutations are strongly 
associated with smoking. However, the distinction 
they provide is not perfect. In addition, the C>A 
transversions signature was associated with 
smoking-caused cancers of the lung [21]. Prof. 
Stathopoulos described that in their study they 
triggered lung cancer and COPD models in mice using 
tobacco chemicals. The tumours developed in mice 
were highly similar to human smoke-induced lung 
adenocarcinomas [22]. The talk went on to discuss 
role of club cells in tobacco chemical-induced lung 
adenocarcinomas using the examples of their mouse 
model experimental studies. Club cells were shown 
to survive KRAS mutations and to form lung tumours 
after tobacco carcinogen exposure. Increasing 
numbers of club cells were found in the alveoli 
with ageing and after lung injury but go undetected 
since they express alveolar proteins. Ablation of club 
cells prevents chemical lung tumours and causes 
alveolar destruction in adult mice [23]. Therefore, 
club cells are important in alveolar maintenance 
and carcinogenesis and may be a therapeutic target 
against pre-malignancy and chronic lung disease.
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Lessons from limb regeneration of 
the axolotl
Regenerative capacity varies widely across species; 
some species are highly regenerative where they 
can recreate a whole body from any piece such 
as planarians, while others can regenerate an 
amputated limb such as lizards, and finally some 
species, such as humans, have a highly limited 
regenerative capacity. The keynote lecture was 
given by Nicholas Leigh (Lund, Sweden) on the 
cells and genes responsible for limb regeneration 
in the Mexican salamander (i.e. the axolotl). Dr. 
Leigh highlighted how scRNAseq has allowed us 
to uncover the cellular composition during axolotl 
limb regeneration [24].
The salamander is a neotenic aquatic species 
capable of fully regenerating its amputated limb 
while preserving all the anatomical structures 
[25]. Similar to a human limb, the salamander 
contains muscles, nervous system, vasculature, 
and a bone structure resembling that of a human. 
Once a limb is amputated, a tissue structure, called 
the blastema, will form and is responsible for the 
regeneration of the whole limb. The blastema is 
rich in a pool of restricted progenitor cells and 
was found to contain epithelial, mesenchymal 
and haematopoietic cell populations and a 
massive influx of immune cells across all stages 
of regeneration [24].
Several of the vertebrate species remain 
regeneration competent, such as amphibians, 
lungfish and Polypterids, while Amniota species 
are regeneration incompetent. These species share 
similar anatomical structures and cell types but 
different regenerative capacities. Leigh et al. [26] 
screened for potential genes that are only present 
in the salamander blastema during regeneration 
and found von Willebrand Factor D and EGF 
domains (vwde) to be actively expressed through 
limb regeneration of several species. Inhibiting 
the translation of vwde using morpholinos in the 
salamander resulted in impaired limb regeneration 
[26]. Vwde orthologs in higher species (mouse, 
chick, human) do exist, however with a lower 
number of EGF domains. It was found that 42.7% 
of human genomes tend to have a loss-of-function 
copy of vwde, which could indicate a drift towards 
their inactivation in humans [26, 27]. Leigh et 
al. [26] speculate that the lack of a blastema in 
regeneration-incompetent species resulted in loss-
of-functions in blastema-specific genes in these 
species.
There are several theories that attempt to explain 
why regeneration-incompetent species lack the 
ability to regenerate such as the development of 
a more intricate and complex adaptive immune 
system. However, the reasons behind this lack of 
regenerative capacity remain unclear. Learning the 
processes by which regenerative species function 
may allow for uncovering mechanisms of activating 
regeneration in injury and disease.
Cell–matrix interactions in the 
lung and beyond
The extracellular matrix is the main structural 
support of the various cell types in the lung and 
various organs. Changes in extracellular matrix 
composition have been associated with several 
chronic disease phenotypes. As an example, COPD is 
characterised by emphysema which is represented 
by the destruction of parenchymal regions where 
gas exchange occurs. By contrast, diseases like 
IPF are characterised by the excessive deposition 
of extracellular matrix components, and the 
subsequent increase in the tissue stiffness. In both 
of these practically opposite cases, the extracellular 
matrix plays a pivotal role in these chronic diseases. 
In this session, Janette Burgess (Groningen, the 
Netherlands) shed light on the important aspects 
of extracellular matrix cell interactions in chronic 
lung disease, followed by Sara Wickström (Helsinki, 
Finland) whose work explores the role of mechanical 
cues on cell fate and integrity of the skin.
There are possibly two major ways in which the 
extracellular matrix can exert its interaction with 
the cells. First, changes in extracellular matrix 
composition and amount can lead to change in 
cellular behaviour. For example, extracellular matrix 
derived from asthmatic airway smooth muscle cells 
lead to increased proliferation of newly seeded cells 
in comparison to extracellular matrix obtained 
from healthy cells [28]. This indicates that matrix 
components deposited in the pathologic state 
contribute to such an effect. Among these factors 
is a small molecule, fibulin-1, which when knocked 
down, was shown to impair cellular migration in a 
wound closure assay [29]. Furthermore, a fibulin-1c 
knockout mouse was shown to decrease collagen 
deposition in the bleomycin-induced fibrosis model. 
This knockout was also associated with lower TGF-β 
activation [30].
Second, changes in matrix organisation, topology 
and stiffness also influence cell behaviour. More 
organised collagen fibres are associated with 
chronic diseases such as IPF. Organisation of 
collagen fibres is driven by several processes 
including enzymatic crosslinkers, such as the lysyl 
oxidase (LOX) family enzymes. LOX not only cross-
links collagens but was also found to influence 
extracellular matrix cues [31]. Inhibition of LOX 
activity using a small molecule inhibitor attenuated 
the effect TGF-β driven remodelling of collagen I, 
which led to impaired cell adhesion and proliferation 
[31, 32]. Moreover, this inhibition of LOX activity 
has also resulted in a decrease of TGF-β induced 
stiffness. The matrix topology also affects various 
cell behaviours such as macrophage infiltration.
The extracellular matrix is also able to influence 
the function of progenitor cells through its 
composition, structure and mechanical cues. 
Sara Wickström talked about her work in the 
regulation of stem cell renewal and differentiation 
in the skin and how it is altered by mechanical 
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cues. Lineage tracing has revealed that there 
is an equilibrium between self-renewal and 
differentiation in epidermis stem cells during 
homeostasis and this equilibrium is disrupted 
during tissue growth in a non-isotropic manner 
[33]. The stem cells were proliferating following the 
arrangement of the collagen fibres on which they 
resided. Experimentally stretching the cells biaxially 
resulted in a major repressive transcriptomic profile 
change where the unifying aspect of the changed 
genes were the regulation of histone modification, 
specifically H3K27 trimethylation which was found 
at the promoter regions of lineage genes leading 
to an attenuation of differentiation [33]. Nuclei 
softening occurred in response to stretching as a 
protective mechanism and adaptation; cells where 
nuclear softening was inhibited were ruptured 
during stretch. The protective nuclear softening 
led to the increase in H3K27me3 and repression of 
lineage-related genes and, in turn, the attenuation 
of differentiation [34].
Therapies: organoids, drugs, cell 
therapy
Carla Kim (Boston, USA) started the final session 
of the LSC 2021 by discussing how lung organoid 
culture techniques can be used to understand 
mechanisms of lung disease. The development of an 
organoid system revealed epithelial–mesenchymal 
mechanisms of bronchopulmonary dysplasia (BPD) 
and mimicked features of the disease. She found 
mesenchymal cells from hyperoxic BPD mice 
decreased alveolar organoid formation efficiency, 
providing evidence that mesenchymal cells may be 
critical in BPD disease. Prof. Kim also explained how 
AT2 organoid cultures derived from DsRed mice 
can be used to interrogate mechanisms of lung 
progenitor transplantation. Organoid cells engraft, 
return to a transcriptional state like their native 
counterparts and proliferate showing evidence 
that transplanted cells can retain their progenitor 
activity.
In the penultimate talk of LSC 2021, Pieter 
Hiemstra (Leiden, the Netherlands) provided an 
excellent overview of the current state-of-the-art 
of the mesenchymal stromal cell (MSC) therapy 
field, with particular insight on MSCs for severe 
emphysema. MSCs have shown promise in vitro and 
in animal models for many years now; however, 
there has been limited success in the translation 
to clinical medicine. Prof. Hiemstra discussed how 
the lack of clinical efficacy may be associated with 
several factors such as the origin of the MSCs, 
dosage and route of administration. Prof. Hiemstra 
also discussed clinical studies in emphysema where 
MSCs were infused into patients after the first stage 
of two-stage lung volume reduction surgery [35]. 
This unique approach provides a better opportunity 
to determine the effect of MSC therapy in a clinical 
setting by directly comparing patient lung tissue 
before and after MSC infusion.
The final talk of LSC 2021 was given by Filipe 
Pereira (Lund, Sweden) who discussed cellular 
reprogramming of cancer cells to antigen-
presenting cells. Prof. Pereira initially showed 
that fibroblasts could be directly reprogrammed 
into antigen-presenting “induced” dendritic cells 
using the transcription factors PU.1, IRF8, and 
BATF3 [36]. Then, it was shown that the same 
could be performed with primary lung carcinoma 
cells and lung cancer-associated fibroblasts. This 
cellular reprogramming harnesses the ability to 
impose antigen presentation directly in tumour 
cells. Reprogrammed cancer cells downregulate cell 
cycle genes thus losing their tumourigenic capacity 
whilst also secreting inflammatory cytokines and 
cross-presenting endogenous antigens to T-cells. 
Prof. Pereira provided insight into the future 
prospects of directly targeting solid tumours with 
the combination of transcription factors and, in 
doing so, merging cellular reprogramming with 
cancer immunotherapy by turning cancer cells 
against themselves.
Early-career delegates session
The early-career delegates session started with a 
brief introduction by current ERS ECMC Chair Niki 
Ubags (Epalinges, Switzerland). Dr. Ubags talked 
about ways of getting involved and taking active 
roles in ERS ECMC. In addition, Dr. Ubags stated the 
objectives of ECMC which are supporting ECMs to 
fully utilise the opportunities provided by ERS, and 
to support ECMs to flourish within ERS and apply for 
leadership roles. The next speaker, Darcy Wagner 
(Lund, Sweden), discussed the use of preprints 
in publishing science. A preprint is a scientific 
manuscript that is uploaded by the authors to a 
public server. Preprints allow scientists to directly 
control the dissemination of their work to the 
worldwide scientific community. The history of 
preprints started in 1961, and bioRxiv launched 
in 2013, covering life sciences and basic science; 
medRxiv launched in 2019 covering clinical 
sciences [37]. Preprints are important to accelerate 
science communication and facilitate networking. 
Dr. Wagner also mentioned “dos” and “don’ts” of 
preprints.
Pieter Hiemstra (Leiden, the Netherlands) 
talked about how to write a peer review, which is 
also considered as a tool for scientific gatekeeping. 
Prof. Hiemstra started describing the steps of the 
submission and review process. Poor experimental 
design, unjustified conclusion, poor readability, 
poor introduction and review of literature, poorly 
described methods, and confusing presentation 
of data are considered as reasons for manuscript 
rejection [38]. Prof. Hiemstra pointed out that 
there are important rules for reviewers to write 
their comments to the authors and the editor. 
The comments to the authors should not include 
any statements on whether the paper should be 
accepted or rejected. The talk continued with 
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the recommendations for feedback, suggestions 
that should be professional, positive and polite. 
Prof. Hiemstra pointed out that “every decline is 
a disappointment”; therefore, careful review and 
thoughtful consideration is needed.
Martin Kolb (Hamilton, Canada) presented a 
talk entitled “How to make me like your paper”. 
Prof. Kolb described the 4A principles of successful 
scientific writing: Aim, Audience, Awareness, 
Articulation. Afterwards, Prof. Kolb mentioned the 
joy of writing a paper and underlined that “Science 
is writing”. Your customers could be readers from 
different disciplines, but the key reader is the 
reviewer. Prof. Kolb pointed out that aligning 
the well-written manuscript to the scope of the 
target journal will reduce chances of manuscript 
rejection. A well-written manuscript is based on a 
clear understanding of the key message. Originality, 
importance, robustness of the data are also main 
points for overall assessment. Another important 
point is how to respond to reviewers. Writing in a 
polite way as well as sleeping 3–4 nights before 
responding to reviewers are recommended steps 
before covering every point raised by the reviewers.
The last speaker of this session, Susanne Herold 
(Giessen, Germany) talked about how to write an 
editorial. Prof. Herold described the features of 
an ideal editorial: it should be an opinion maker, 
reconciliatory, and balanced but crusading [39]. 
Additionally, an editorial should: 1) provide the 
own intellectual contribution of the authors, rather 
than just repeating or summarising the findings 
of the publication it refers to; 2) critically discuss 
the new findings against the background of current 
knowledge and evidence; 3) formulate viewpoints 
based on objective analyses; and 4) provide a 
refreshing view of the topic. It is important that 
an editorial is well-balanced in its statements, 
objective and fair, e.g. it should express an opinion 
without being opinionated. Moreover, an editorial 
can critically state limitations of the presented 
publication but should provide suggestions on 
how to overcome these in the future. In general, 
an editorial should leave a good aftertaste and 
stimulate the reader’s interest in the scientific 
article it refers to. Summary illustrations are a 
welcome addition to an editorial.
Young investigator session
The five highest ranked abstracts submitted to 
the LSC by early-career delegates were presented 
during the Young Investigator session. Simon Coyle 
Rowan (Dublin, Ireland) kicked of the session by 
discussing pulmonary mesenchymal populations 
present in the healthy and IPF lung. Dr. Rowan 
showed that pulmonary mesenchymal cells are a 
conglomeration of molecularly distinct subtypes and 
that the transcriptomic signatures of each subtype 
are conserved between species. Importantly, Dr. 
Rowan showed that all mesenchymal subtypes 
can contribute to scarring in IPF. Martina M. De 
Santis (Lund, Sweden) described the development 
of a novel bioink for 3D bioprinting lung tissue 
[40]. This bioink, known as an extracellular-
matrix-reinforced (rECM) bioink, can be used to 
bioprint human small airways. rECM bioinks were 
shown to be biocompatible when implanted in 
both immunodeficient and immunocompetent 
mice and allowed for vascular infiltration from 
the surrounding tissue. In the next talk, Georgia 
A. Giotopoulou (Munich, Germany) described a 
novel candidate lung tumour promoter: the cAMP 
response element-binding (CREB) protein. CREB is a 
regulator of key cellular processes such as survival, 
proliferation, differentiation and inflammation, 
and is involved in the development of normal 
respiratory epithelium. Her talk showed that 
CREB also mediates the immune-evasion of KRAS 
mutant lung adenocarcinoma by preventing the 
recruitment of tumouricidal neutrophils. Next, Pien 
Goldsteen (Groningen, the Netherlands) described 
the development of a lung on a chip model with the 
final aim to study neuronal innervation of airway 
smooth muscle cells in asthma and as a drug 
screening platform. For this, Goldsteen developed 
a novel protocol to derive airway cholinergic neurons 
from human pluripotent stem cells and combined 
the pluripotent derived airway cholinergic neurons 
with organ on a chip technology. In the final talk, 
Ying Wang (Leiden, the Netherlands) proposed 
the use of differentiated primary human airway 
epithelial models to study severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection 
biology and pathogenesis. Interestingly, Wang 
identified bronchial epithelial cell maturation and 
differentiation as a contributing factor to airway 
susceptibility to SARS-CoV-2.
In conclusion, the virtual LSC 2021 was an 
inspiring meeting, where great science was 
presented along with a variety of career development 
opportunities for ERS ECMs. We can only highly 
recommend this meeting and encourage all ECMs 
to be part of this conference again next year!
Highlights from the 
ERS/European Sleep 
Research Society Sleep and 
Breathing 2021
The SBC 2021 took place online on 16–17 
April 2021, connecting respiratory medicine 
professionals on an international level to discuss 
the latest updates in sleep medicine from a clinical, 
translational and basic science perspective.
Here, ECMs of ERS Assembly 4 have aimed 
to summarise some of the newest insights 
presented during the symposia and oral sessions 
of the SBC 2021. Each section has been written 
by ECMs specialised in the different fields of this 
interdisciplinary assembly. Take-home messages 
from the conference sessions are provided in table 2.
8 Breathe | 2021 | Volume 17 | No 3
Highlights of the ERS LSC and SBC 2021 and the new ECMC members
Sleep disordered breathing and 
cardiovascular disease: still an 
open problem
Obstructive sleep apnoea (OSA) among patients 
with coronary artery disease (CAD) has a prevalence 
of 16% [41]. Observational studies showed the 
beneficial effects of continuous positive airway 
pressure (CPAP) on cardiovascular outcomes in sleep 
clinic cohorts. Nevertheless, evidence by means of 
randomised controlled trials with cardiovascular 
cohorts is currently lacking [42].
The RICCADSA Study included non-sleepy OSA 
patients with newly revascularised CAD and an 
apnoea–hypopnoea index (AHI) >15 events per h, 
randomised to auto-titrating CPAP or no CPAP. A 
significant beneficial effect of CPAP on repeated 
revascularisation, new myocardial infarction, stroke 
and death attributed to cardiovascular causes was 
seen only after adjusting for baseline comorbidities 
and CPAP adherence [43].
In the SAVE trial, participants with coronary or 
cerebrovascular disease and moderate-to-severe 
OSA were randomised to CPAP treatment or usual 
care with no OSA therapy. CPAP therapy showed 
no significant effect on the prevention of recurrent 
serious cardiovascular events, though significantly 
reducing sleepiness among other OSA symptoms 
and improving quality of life [44].
The ISAACC trial included non-sleepy OSA 
patients who performed apnoea sleep testing within 
3 days after acute coronary syndrome, randomised 
to CPAP therapy and usual care or usual care alone. 
The presence of OSA was not associated with an 
increased prevalence of cardiovascular events. 
Interestingly, CPAP treatment, although with an 
average use of 2.8 h per night, did not significantly 
reduce this prevalence [45].
Renata Riha (Edinburgh, UK) focused on the 
link between OSA and stroke. In cerebrovascular 
patients, severe OSA is a rather common condition 
[46], with a particularly high stroke risk if left 
untreated [47]. However, many factors influence 
CPAP efficacy, e.g. where the stroke occurred and 
the level of residual impairment [48]. Similarly, 
insomnia slightly increases the cardiovascular risk 
[47]. The role of other forms of sleep disordered 
breathing in increasing cardiovascular risk needs 
to be further investigated.
Carolina Lombardi (Milan, Italy) highlighted the 
importance of early diagnosis and treatment of OSA 
in patients with atrial fibrillation (AF). The estimated 
prevalence of OSA in patients with AF ranges up to 
80% [49]. An elevated AHI represents a risk factor 
for incidental, paroxysmal and recurrent AF [50]. The 
hypoxic burden is considered a key factor in elevated 
cardiovascular risk among OSA patients. A cross-
sectional analysis of the ESADA [51] cohort showed 
a link between AHI and arrhythmias prevalence in 
relation to OSA severity and CHA2Ds2-VASc score. 
Moreover, central hypopnoeas observed in the 
AHI computation suggested that these could be 
a consequence of rather than a cause of AF. It is 
still unclear if central apnoeas and hypopnoeas 
Table 2 Take-home messages from the Sleep and Breathing Conference 2021




still an open problem
Symposium Cardiovascular risk factors need to be better quantified in obstructive sleep 
apnoea (OSA) patients.
Sleep disordered breathing other than OSA and its association with 
cardiovascular risk should be considered for further studies.
Sleep apnoea and cancer: 
how strong is the link?
Pro/con debate Potential OSA-related tumourigenic mechanisms can be listed as intermittent 
hypoxaemia, sleep fragmentation and circadian cycle disruption.
The results of current epidemiological studies have not supported the evidence 
obtained by translational research. Further research is needed especially 
on single organ cancer type, the effect of OSA treatment, and OSA-related 
specific cancer biomarkers.
Circadian disruption in 
sleep and health
Symposium Circadian disruption may increase the susceptibility to mental disorders.
The daylight-saving time should be carefully revised, given its debatable 
importance and potential adverse consequences.
Treatment and 
management of sleep 
respiratory diseases
Oral presentation Not only continuous positive airway pressure (CPAP) therapy, but also other 
therapy options provide benefit on the management of OSA and OSA-related 
symptoms.
Focusing on pharmacological treatment of OSA: pitolisant and solriamfetol 
seemed to improve OSA-associated excessive daytime sleepiness.
Sleep in the new era of 
COVID
Symposium The coronavirus disease 2019 (COVID-19) pandemic has a great impact on 
sleep quality and sleep disorders across all age groups as well as a reduction 
of sleep medicine services.
Sleep medicine faces new challenges due to the pandemic that can be 
answered by e-health services and implementation of new technologies.
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could be a specific target for treatment in patients 
with AF and OSA [52]. Furthermore, an elevated 
night-to-night variability of AHI has been observed 
in this patient population and associated with 
haemodynamic and ventilatory instability, thus 
suggesting the need for long-term monitoring 
and treatment optimisation [53]. In addition, 
autonomic imbalance was associated with a higher 
risk of cardiovascular events and arrhythmogenesis 
in OSA [54]. In conclusion, further research is 
needed for better phenotyping of OSA patients 
with cardiovascular diseases to quantify their 
cardiovascular risk.
Sleep apnoea and cancer: how 
strong is the link?
All conflicting aspects of the relationship between 
OSA and cancer were presented as a pro/con debate. 
Isaac Almendros (Barcelona, Spain) presented the 
pro side by showing the evidence on the effects of 
intermittent hypoxaemia and sleep fragmentation 
on tumourigenesis [55, 56]. First, Prof. Almendros 
mentioned the results of translational research 
proving that both intermittent hypoxaemia and 
sleep fragmentation accelerate tumour growth [56, 
57]. In studies in which OSA challenge was applied 
to animals, the tumour growth, carcinogenesis, 
invasion and angiogenesis were investigated in 
mice with different types of tumours, including 
melanoma, myeloma, lung, breast, colon and 
kidney cancers. Inflammation, oxidative stress, 
sympathetic activation and immune deregulation 
were shown to be potential underlying mechanisms. 
However, the clinical data regarding melanoma, 
breast and lung cancer showed no statistically 
significant result. Despite the limitations and the 
conflicting results of previous studies, melanoma 
emerges as the type of tumour most likely to be 
OSA-related in terms of incidence and aggressiveness. 
Except for the studies focusing on cutaneous 
melanoma, the large-scale epidemiological studies 
including different types of cancers have not shown 
any result supporting laboratory evidence at the 
moment. Some potential confounding factors include 
genetic heterogeneity, multiple mutations, obesity 
and other comorbidities, OSA severity and age of 
the patients [57]. An in vitro study proved that the 
effect of intermittent hypoxaemia on tumourigenesis 
varies according to the magnitude of hypoxia and 
the cell line [58]. It is also known that ageing and 
obesity reduce the effect of intermittent hypoxaemia 
on tumour growth in mice [56, 59]. In conclusion, 
further research is needed for highlighting the 
association between OSA and cancer and assessing 
the role of these confounders.
On the opposite side, Maria Bonsignore 
(Palermo, Italy) showed how OSA and cancer have 
some common risk and protective factors. Evidence 
showing an effect of CPAP on lung cancer is currently 
lacking. Moreover, the epidemiological studies do 
not support the link between OSA and cancer in 
terms of incidence, metastasis risk and mortality 
[60, 61]. The uncertain effect of age, the lack of data 
on the preventive role of OSA treatment and the 
difficulties in establishing the temporal relationship 
between OSA and cancer represent currently crucial 
issues. It has been shown that OSA increases the 
incidence of melanoma, kidney and pancreas 
cancer. Conversely, a decrease in the incidence 
of breast, prostate, colon and rectum cancer was 
observed [62]. Future prospective studies with large 
patient cohorts might focus on a single organ cancer 
type and OSA-related specific cancer biomarkers. 
Furthermore, as the circadian cycle alters cancer 
cell dissemination [63], the influence of OSA on 
circadian cycle disruption might be also addressed 
in future research. In conclusion, more evidence is 
needed to conclude that OSA plays a role in human 
cancer.
Circadian disruption in sleep and 
health
The symposium presented by Tiina Paunio (Helsinki, 
Finland) and Erna Sif Arnardóttir (Reykjavik, Iceland) 
highlighted the importance of circadian rhythms for 
mental health. The daylight-saving time adopted 
in several territories around the world was critically 
appraised and a brief overview of the current state 
of European countries in this regard was presented.
Alterations in circadian rhythms such as phase 
delay, decreased amplitude and high instability are 
often experienced by individuals with psychiatric 
disorders [64–68]. However, the association 
between circadian rhythms and mental health is 
not completely understood and further studies 
investigating the causality between these factors are 
needed. Tiina Paunio presented aetiological models 
possibly explaining this relationship [69]. On one 
hand, circadian disruption may contribute to an 
increased risk of mental disorders. A second model 
suggests that mental disorders and their treatments 
lead to alterations in circadian rhythms, while the 
third model considers both possibilities, suggesting 
a bi-directional relationship between these factors.
Several circadian-related characteristics and 
behaviours may account for different susceptibilities 
to mental disorders. Accordingly, the individual 
timing preference (chronotype) is associated with 
a higher rate of various mental disorders including 
seasonal and bipolar depression [70–72]. In 
addition, inappropriate exposure to light due to 
social schedules, such as shift work and jetlag, 
demonstrably affects the circadian rhythms and 
consequently increases the susceptibility to mental 
disorders [73–75]. Considering this, interventions 
controlling the light exposure are interesting options 
to prevent alterations in circadian rhythms and their 
undesirable consequences.
Under this scenario, the daylight-saving time 
adopted in several countries around the world 
needs to be critically evaluated for its relevance and 
associated outcomes. Erna Sif Arnardóttir presented 
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an overview of the scientific community’s attempts 
in promoting awareness and changes in relation 
to this aspect. Considering the debatable rationale 
underlying the use of daylight-saving time and 
potential adverse outcomes associated with it 
[76, 77], on 12 September 2018, the European 
Commission presented a proposal to dispense 
with the biannual clock changes. This was later 
supported by the European Parliament on 26 
March 2019, letting each member state decide 
whether they would keep the daylight-saving time 
or the standard time [78]. However, this was not 
effectively implemented up to the present date, 
arguably due to the coronavirus disease 2019 
(COVID-19) pandemic.
The European Sleep Research Society, in 
association with the European Biological Rhythms 
Society and the Society for Research on Biological 
Rhythms, state that the current scientific knowledge 
supports the use of standard time over daylight-
saving time during summer or year-round for better 
sleep and general health [79, 80]. This position 
is seconded by the American Academy of Sleep 
Medicine, which highlights the acute effects of 
daylight-saving time such as the increased risk of 
cardiovascular events, traffic accidents, and mood 
disorders [81].
In summary, the symposium addressed the 
importance of circadian rhythms for mental 
health, demonstrating factors with the potential 
to disrupt these rhythms and ultimately increase the 
susceptibility to mental disorders. Considering this, 
the maintenance of the daylight-saving time should 
be carefully revised, given its debatable importance 
and potential adverse consequences.
Treatment and management of 
sleep respiratory diseases
This oral communication session provided new 
insights on OSA treatment options.
Martina Meszaros (Budapest, Hungary) 
presented the work carried out by her team on 
the assessment of night-to-night variability 
of the oxygen desaturation index based on 
two consecutive nocturnal pulse oximetry 
measurements. They found that night-to-night 
variability was high in OSA, and more than 30% of 
patients changed severity class within two nights. 
The mean change in the oxygen desaturation 
index between two nights was almost 7 per h and 
increased with OSA severity.
Kallirroi Lamprou (Athens, Greece) presented a 
study conducted by her team on the discrepancy 
between patient- and partner-reported daytime 
sleepiness measured with the Epworth Sleepiness 
Scale (ESS). This study did not find significant 
differences in ESS scores at baseline or after 
3 months on CPAP.
Izolde Bouloukaki (Heraklion, Greece) 
investigated the effect of positive airway pressure 
(PAP) on mortality and hospitalisation caused 
by COPD exacerbations. Improved survival and 
hospitalisation rates were associated with ≥6 h of 
PAP. Moreover, ESS values and Beck Depression 
Scale values were also improved by PAP, suggesting 
that it also has an impact on several aspects of 
health-related quality of life.
Focusing on pharmacological treatment of OSA, 
Yves Dauvilliers (Montpellier, France) showed the 
findings of a study on the effects of pitolisant 
on excessive daytime sleepiness [82]. Pitolisant 
reduced the ESS score and improved the sleep 
latency test and Pichot fatigue score. Frederick 
Vickenbosch (Maastricht, the Netherlands) 
showed a positive effect of solriamfetol on driving 
performance. The results suggested both drugs 
could be potential options for treating excessive 
daytime sleepiness in OSA.
Laetitia S. Gaspar (Coimbra, Portugal) provided 
information about the impact of short- and long-
term CPAP on biological clock disruption in OSA. 
Long-term CPAP therapy seemed to improve 
OSA-associated clock disruption as shown 
by melatonin levels, cortisol levels and body 
temperature.
Francisco V. Machado (Porto, Portugal) showed 
that 82% of the patients were diagnosed with 
OSA in the primary care. The unexpectedly high 
number of patients with OSA suggested that 
sleep laboratories should have more focus on 
large screening programmes and standardised 
referral protocols in collaboration with primary 
care. However, CPAP is the only universally funded 
OSA treatment option. Nevertheless, Sean Treanor 
(Manchester, UK) concluded that up to 56.8% of 
patients on CPAP are uncompliant with treatment. 
Mandibular advancement devices (MAD) were 
presented as a cost-effective treatment option for 
these patients.
Lishun Yue (Beijing, China) and colleagues 
investigated different expiratory positive airway 
pressure (EPAP) levels of noninvasive ventilation 
(NIV) in elderly patients with OSA. There were 
significant differences in leakage between fixed-
scale EPAP and wide-scale EPAP. Intra-abdominal 
hypertension had a lower prevalence in the wide-
scale EPAP group. Moreover, the occurrence of 
patient–ventilator desynchronisation was higher 
in the fixed EPAP group. Varying EPAP levels 
seemed to be more comfortable for older patients 
with OSA.
Abdelkebir Sabil (Paris, France) and his team 
investigated the prevalence of predominant 
positional OSA (p-POSA) and exclusive positional 
OSA (e-POSA) and the outcomes of CPAP in 
these patients. p-POSA and e-POSA were highly 
prevalent (53.5% and 20.1%, respectively). 
Patients with p-POSA and e-POSA showed a 
lower CPAP compliance after 6 months compared 
with patients without positional OSA. These data 
suggest that CPAP may not be the optimal choice 
in positional OSA.
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In summary, therapy options other than CPAP 
were shown to provide benefit in OSA and its 
symptoms.
Sleep in the new era of COVID
The symposium focused on the role of COVID-19 
in OSA.
Winfried Randerath (Solingen, Germany) 
presented the relationship between obesity, sleep 
apnoea and COVID-19. Obesity, a frequent medical 
condition, is a risk factor for severe course of the 
disease in patients with COVID-19, especially the 
younger ones, including admission in the intensive 
care unit and potential need for invasive mechanical 
ventilation [83, 84]. High inflammatory status, 
disturbed metabolism and impaired cardiac and lung 
function are considered factors that may increase 
the severity of COVID-19 in these patients [85, 86]. 
Patients with COVID-19 and OSA seemed to have 
higher mortality rates; however, more research is 
needed to identify possible mechanisms linking 
the severity of COVID-19 with OSA, such as the 
involvement of the renin–angiotensin–aldosterone 
system, the cardiovascular consequences in OSA 
and cardiac complications in COVID-19 and the 
accentuation of COVID-19 coagulopathy due to 
OSA [87].
The COVID-19 pandemic, lockdown and home 
confinement resulted in a great impact on sleep, 
as discussed by Sophia E. Schiza (Heraklion, 
Greece). Healthy individuals, as well as healthcare 
workers, reported impairments in the sleep quality, 
nightmares and features of insomnia compared 
with the pre-pandemic period [88–90]. Anxiety, 
depressive symptoms and stress may have led 
to sleep disturbances and exposure to screens 
near bedtime. Female sex, younger age and 
financial difficulties due to the pandemic were 
factors associated with worse sleep quality and 
increased use of sleeping medications [88, 91]. 
Additionally, patients with COVID-19 reported sleep 
disturbances, fatigue and muscle weakness after 
hospitalisation, potentially representing features 
of post COVID-19 syndrome [92]. Managing 
sleep disturbances during lockdown and home 
confinement is of great importance as they may 
have long-lasting effects on the overall health 
status. More research is needed for assessing 
possible mechanisms and treatment of sleep 
disturbances after COVID-19.
Refika Hamutcu Ersu (Ottawa, Canada) 
showed that the COVID-19 pandemic caused 
sleep disturbances in young children, although 
the total duration of sleep was stable over 24 h 
and nocturnal sleep duration was increased due 
to online school [93, 94]. Children had difficulties 
in initiating and maintaining sleep and showed an 
increased frequency of parasomnias. Furthermore, 
lockdown led to changes in children’s lifestyle, e.g. 
decreasing sport activities [95]. The closure of 
sleep laboratories and the delay in ear–nose–throat 
surgical procedures during the COVID-19 pandemic 
changed routine paediatric sleep practice [96]. 
Alternatives like telemedicine, home sleep studies 
and nonsurgical treatment options may be 
considered for management [97]. Moreover, there 
are limited data suggesting that OSA in children may 
be a risk factor for developing severe COVID-19 as 
it is in the adult population.
Ludger Grote (Göteborg, Sweden) presented 
the changes in sleep medicine and practice due 
to COVID-19. During the pandemic, there was a 
substantial reduction in both diagnostic procedures 
and initiation of PAP treatment of sleep disordered 
breathing [16, 17]. Moreover, the staff in sleep 
laboratories was reduced up to 25% due to their 
re-allocation to COVID-19 units [98]. Although there 
are guidelines from scientific societies on mitigation 
strategies and reopening of sleep laboratories, until 
now sleep medicine services are not fully recovered. 
E-health services like telemedicine may facilitate 
sleep disordered breathing management during the 
COVID-19 pandemic with home sleep studies and 
remote monitoring [97]. Prioritisation of patients 
in large waiting lists after the COVID-19 pandemic 
with the use of e-health services is a point to be 
assessed by future research.
Meet the new members of the 
ECMC
The ECMC is composed of 14 members, one ECM 
representative per assembly of the ERS. The ECMC 
members work together to ensure that ECMs are 
well-represented in ERS committees, councils and 
assemblies, to provide them with opportunities 
for professional development and education, and 
to encourage them to flourish within ERS and to 
apply for leadership roles. An overview of the 
activities carried out by the ECMC is described 
elsewhere [99].
Every 3 years, elections are held for the position 
of ECM representative for each assembly. This 
year, five new elected ECM representatives joined 
the ECMC. Below we introduce each of the new 
ECM representatives of Assemblies 1, 4, 10, 12 
and 13.
Assembly 1: Thomas Gille
Thomas Gille is the new ECM representative 
of Assembly 1 (Respiratory clinical care and 
physiology). He is a former respiratory physician, 
presently Associate Professor of Physiology 
in Université Sorbonne Paris Nord/Hôpitaux 
Universitaires de Paris Seine-St-Denis and a 
member of Inserm laboratory “Hypoxia and the 
Lung” (Director: Prof. C. Planès), Bobigny, France. 
He is currently involved in several official societies 
of respiratory medicine and physiology. His 
translational research is mainly about interstitial 
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lung diseases (especially pathogenesis, functional 
explorations at rest and exercise, associated sleep 
disorders, dyspnoea, post COVID-19 sequelae) and 
alveolar epithelial cells (biological and functional 
properties in normal and pathological conditions, 
particularly sustained or intermittent hypoxia). He 
also has a special interest in spirometry in primary 
care and simulation-based medical education.
Assembly 4: Matteo Bradicich
Matteo Bradicich is the new ECM representative 
of ERS Assembly 4 (Sleep disordered breathing). 
He is currently working as a resident physician 
at Felix Platter University Center for Geriatric 
Medicine in Basel (Switzerland), in the framework 
of the specialisation programme in internal 
medicine and pulmonology. He graduated at the 
University of Pisa (Italy) in 2017 with a joint final 
dissertation at the University of Pisa (Italy) and 
University of Oxford (UK), under the supervision 
of Prof. Pierluigi Paggiaro and Prof. Ian Pavord. 
He worked as research clinician in the Respiratory 
Pathophysiology ward of Cisanello University 
Hospital of Pisa (Italy), mainly working with 
patients with asthma, COPD and eosinophilic 
granulomatosis with polyangiitis. Moreover, he 
worked during this period as data manager for 
the Severe Asthma Network Italy (SANI). Since the 
end of 2018, he is affiliated to the Department 
of Pulmonology and Sleep Disorders Centre of 
the University Hospital Zurich (Switzerland) and 
focuses on OSA. In 2021, he was awarded the Dr. 
med. title at the University of Zurich (Switzerland) 
with a doctoral thesis on heart rate variability 
in OSA. His main research topics in the field of 
sleep medicine are OSA-related cardiovascular 
pathophysiology, domotics applied to sleep 
disordered breathing and OSA diagnostics.
Assembly 10: Holly R. Keir
Holly Keir is the new ECM representative of 
Assembly 10 (Respiratory infections). She is a 
postdoctoral researcher working at the University 
of Dundee Ninewells Hospital, UK. She completed 
her undergraduate degree in Biological Sciences 
at the University of Dundee (UK) in 2016 before 
joining the Chalmers laboratory. Her research 
interests are in the role of neutrophilic function 
and the lung microbiome in patients with 
bronchiectasis and COPD. She is in the final stages 
of completing her PhD investigating the role of 
neutrophil extracellular trap formation in chronic 
lung disease.
Assembly 12: Catharina C. Moor
Catharina Moor is the new ECM representative 
of Assembly 12 (Interstitial lung disease). She is 
a pulmonary resident and postdoctoral researcher at 
the Erasmus University Medical Center (Rotterdam, 
the Netherlands). In 2020, she obtained her PhD, 
which focused on innovative approaches to care 
and research in interstitial lung disease, such as 
eHealth solutions, home spirometry, and electronic 
nose technology. As postdoctoral researcher, she 
is involved in many research projects dedicated 
to new innovations, facilitating personalised and 
comprehensive care for patients with interstitial 
lung disease.
Assembly 13: Mona Lichtblau
Mona Lichtblau is the new ECM representative of 
Assembly 13 (Pulmonary hypertension). She is a 
pulmonary resident and postdoctoral researcher 
at the University Hospital of Zurich, Switzerland. 
Albeit being interested in the whole spectrum of 
pneumology, her clinical and research focus is 
the pulmonary vasculature in healthy people and 
in patients with lung diseases, at low and high 
altitude. Furthermore, she is interested in several 
treatment options for patients with pulmonary 
hypertension such as rehabilitation, exercise and 
oxygen therapy.
Final remarks
This article has provided an overview of the LSC and 
SBC highlights. For those who could not attend the 
conferences or who want to re-watch the sessions, 
learning resources are available: 1) recordings of 
the LSC sessions are available to ERS members 
on the e-learning website (www.ers-education.
org/events/conferences/? idP=217272) ; 
2) the SBC replay is available upon registration 
(https://live.sleepandbreathing.org/user/
login). In addition, the abstracts from the LSC 
and SBC 2021 are already available online as a 




We also provided a brief introduction to the new 
members of the ECMC. Please feel free to contact 
the ECM representative of your assembly if you have 
any questions and ideas and/or if you want to be 
more involved in ERS activities. Their contact details 
can be found in the ERS members’ directory. You 
can also sign up to the competence list via myERS 
(https://my.ersnet.org/) and indicate your areas 
of expertise and interests. You can also follow the 
ECMC social network pages:
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